Respiratory diseases call for special attention from clinical and translational science by Chunxue Bai
Bai Translational Respiratory Medicine 2013, 1:1
http://www.transrespmed.com/content/1/1/1EDITORIAL Open AccessRespiratory diseases call for special attention from
clinical and translational science
Chunxue BaiAbstract
Respiratory diseases will become one of the top 3 leading causes of estimated mortality in 2020 and become about
one third of total causes of estimated mortality. The journal of Translational Respiratory Medicine is a truly
international, peer-reviewed journal devoted to the publication of articles on outstanding work with translational
potentials between basic research and clinical application to understanding respiratory disease. Translational
respiratory medicine will more focus on biomarker identification and validation in pulmonary diseases in
combination with clinical informatics, targeted proteomics, bioinformatics, systems medicine, or mathematical
science; on different translational strategies of cell-based therapy to clinical application to treat lung diseases; on
targeted therapies in combination with personalized medicine; and on distant electronic medicine to monitor a
large population of people’s health. Translational Respiratory Medicine is an additional but unique opportunity for
scientists and clinicians who work on pulmonary diseases to publish their outstanding findings, initiative results, and
critical and perceptive opinions in the journal.
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truly international, peer-reviewed journal devoted to the
publication of articles on outstanding work with transla-
tional potentials between basic research and clinical
application to understanding respiratory disease. The
journal provides a forum for exchange of ideas on poten-
tial molecular and cellular mechanisms and novel treat-
ment for respiratory diseases. Translational Respiratory
Medicine aims to play an important, critical, and recog-
nized role in the understanding of human respiratory
diseases and improvement of the prognosis of patients.
Respiratory diseases need global attentions and solu-
tions now more than ever, especially from clinical and
translational medicine. Respiratory diseases have become
the second leading cause of mortality with over 130
major causes according to the WHO Global Burden of
Disease 2000 study’s (GBD 2000) estimates of incidence,
health state prevalence, severity and duration, and mor-
tality for 17 sub-regions of the world [1]. Four out of the
top ten leading causes, accounting for approximatelyCorrespondence: bai.chunxue@zs-hospital.sh.cn
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medium, provided the original work is properly43% of mortality are respiratory diseases such as lower
respiratory infections, chronic obstructive pulmonary
diseases (COPD), and lung cancer. COPD, respiratory
infection and lung cancer will become the top 3 to 5
leading causes of estimated mortality in 2020 and
become about one third of total causes of estimated
mortality in the world, according to the World Health
Report 2002 in WHO website at www.who.int/evidence/
bod. The journal of Translational Respiratory Medicine
is an efficient and effective communication channel for
publishing articles from leading research scientists and
clinicians at the forefront of translational medicine and
bridge basic research and clinical application, with a
special focus on respiratory diseases. Translational
Respiratory Medicine becomes the premier source of
information in the field of translational medicine in
respiratory diseases and one of the leading platforms to
translate basic sciences into clinical use, and clinical
imaging into bioinformatics.
There is solid evidence that translational research on
respiratory diseases has increased greatly. Most current
journals related to pulmonology focus on either molecu-
lar biology or clinical practices. This means that the
most important link between them has been ignored.ccess article distributed under the terms of the Creative Commons Attribution
y/2.0), which permits unrestricted use, distribution, and reproduction in any
cited.
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basic research to clinical application and clinical ques-
tions to bench. Thus, there is a great need to have a crit-
ical and important channel and platform for such
communications. Translational Respiratory Medicine
will promote and accelerate the exchange of bidirec-
tional information on respiratory diseases between basic
and clinical researchers, innovators and clinicians, scien-
tists and politicians, and doctors and patients. Transla-
tional Respiratory Medicine, as a part of clinical and
translational medicine, is intended to optimize new
methodologies, foster clinical application of new thera-
peutic strategies, and ultimately improve the quality of
life for patients with respiratory diseases [2]. Lung can-
cer, together with breast, prostate and gastrointestinal
cancers, were listed and encouraged as a program of
translational research in the National Institutes of
Health guide for Specialized Program of Research Excel-
lence grants for cancer research in 1993 [3], which may
be the earliest national program focused on translational
research. Translational research on respiratory diseases
was one of pioneering examples to understand the
process of translational medicine, although this remains
a continuous process. For example, local therapy with
p53 gene for patients with lung cancer was considered
as an important milestone in translational cancer re-
search in 1996 [4]. Translational science was initially
pointed out as a two-way process between the bench
and clinical application. Translational respiratory medi-
cine opens the opportunity for pulmonary scientists and
clinicians to fight a number of challenges to translate
molecular understanding into clinical applications for
lung diseases.
Biomarkers have been defined as an important factor
in diagnosing the early phase of diseases, monitoring the
severities of the disease and sensitivities to therapies, or
even predicting the prognosis of patients with lung
diseases. An increasing number of biomarkers are being
discovered and identified from preclinical research, while
a few can be used clinically. For example, network bio-
markers and dynamic network biomarkers, a new type
of biomarkers with protein-protein interactions, can be
monitored and evaluated at different stages and time
points during the development of diseases [5]. Recent
study combined genome-wide association with forced
expiratory volume in 1 second and the ratio of forced
expiratory volume in 1 second to forced vital capacity
and identified 16 new regions showing association with
pulmonary function [6]. Those biomarkers were selected
from 48,201 individuals of European ancestry with
follow up of the top associations in up to an additional
46,411 individuals. However, there is further need to
better understand those biomarkers associated with mo-
lecular mechanisms involving pulmonary function andvalidate selected targets preventing lung dysfunction.
Biomarker identification and validation in pulmonary
diseases like COPD stand in the frontline of translational
medicine in combination with clinical informatics, tar-
geted proteomics, bioinformatics, systems medicine, or
mathematical science [7,8]. Translational Respiratory
Medicine is expected to accelerate and standardize the
process from post-validation to authority approval, clin-
ical application to policy and regulation, and individual
medicine to public health.
Increasing evidence from preclinical studies demon-
strated that local or systemic administration of external
mesenchymal or induced pluripotent stem cells could
prevent or treat lung diseases or improve the severity of
diseases, even though the exact mechanism remained
unclear. For example, stem cell-based therapy has been
considered as an attractive new therapeutic approach for
acute lung injury. Multiple paracrine factors produced
from stem cells were proposed to play critical and neces-
sary therapeutic roles in the maintenance of endothelial
and epithelial integrity, down-regulation of both tissue
and circulating inflammation, acceleration of tissue re-
pair process, and/or inhibition of bacterial growth [9]. It
is also possible that endogenous lung stem cells or cell
progenitors may be activated and play an important role
in response to various challenges. Recent study provided
the evidence to show that human lungs contain undiffer-
entiated human lung stem cells nested in niches in the
distal airways, which have capacities of self-renewing,
clonogenic, and multipotent in vitro [10]. Such lung
stem cells, as the source of endodermal and mesodermal
lineages, are different from known regional pools of pro-
genitor cells. This is a new concept for understanding
lung biology and the development of new cures for
debilitating lung diseases and holds new implications for
regenerative medicine to treat lung disease. Those
findings can lead to different translational strategies of
cell-based therapy to clinical application to treat lung
diseases. It is more challenging to translate the experi-
mental efficacy of external stem cells and the existence
of human lung stem cells into the therapies and predic-
tions for lung diseases. However, eventually the first cell-
based clinical trial in acute lung injury has just been
approved by FDA, suggesting new landmark of stem cell
research and may hold promise for patients treatment in
the near future.
A large number of constantly advancing biotechnolo-
gies need to be translated into diagnoses and therapies
for respiratory diseases as new applications to benefit
patients. Genetic engineering to create tumor-fighting
immune cells for cancer therapies has been considered
as one of 5 recent breakthrough innovations in biotech-
nology. The cancer-targeted specific therapy by genetic
engineering of the recipient’s immune system could be
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from lymphocytes of a patient who had an immune re-
sponse to cancer, to lymphocytes from other patients
[11]. The feasibility and clinical responses with adoptive
transfer of ex vivo generated immunologic effector cells
that are capable of targeting metastatic melanoma. The
preliminary study in humans provides evidence of the
feasibility and antitumor activity of genetically modified
lymphocytes achieved by high-capacity viral vectors,
with optimization of the approaches. Such advanced bio-
technologies make it possible to create genetically engi-
neered adoptive Th2 cells or cancer-targeted T-cell
receptor lymphocytes to treat allergic diseases or lung
cancer. We are excited and encouraged by those out-
standing findings and questioned if such approaches can
be translated from other cancers to lung cancer, preclin-
ical trials to clinical application, or potential long-term
risks to safe and durable therapies.
Another topic of translational respiratory medicine is
to translate the understanding of molecular mechanisms
into personalized medicine and therapies and hospital
treatments and manipulations into distant electronic
medicine (eMedicine). We create and establish a system
of distant eMedicine to closely connect people at risk
from respiratory diseases with pulmonologists through
the cloudy system. People can reach the pulmonologist
and report their symptoms and lung function tests in a
real time, without the need to come to the hospital. This
is a new aspect of translational respiratory medicine
from clinical treatment to social prevention, static out-
patient clinic to dynamic and real-time monitoring, and
a small group of patients with respiratory diseases to a
large population of people with any risk of respiratory
disorders or discomfort. Without limits, Translational
Respiratory Medicine will publish papers in all relevant
areas designed to further understand the molecular
mechanisms underlying organ or cell dysfunction in
human pulmonary diseases, dedicated to the discovery
and validation of diagnostic and prognostic disease bio-
markers, and the identification and validation of novel
drug targets, application of tissue genomics, transcrip-
tomics, proteomics and bioinformatics in drug efficacy
and toxicity in clinical research.
Translational Respiratory Medicine will refresh the “old”
clinical topics, e.g. mechanical ventilation and lung func-
tion, and translate clinical challenges and considerations
to molecular biologists to innovate and develop new ther-
apies and supports to patients with lung diseases. One
way is to identify and validate gene and protein biomar-
kers from patients with lung diseases for the correlation
with lung function measurements, even better to follow
up the alternations by time [6]. Or the advanced biotech-
nologies and molecular understanding should be trans-
lated to the clinical research of mechanical ventilation. Forexample, mitochondrial biogenesis and content, respira-
tory chain cytochrome c oxidase, mitochondrial DNA
deletions, lipid accumulation, AMP-activated protein kin-
ase and sirtuins, mitochondria-derived oxidative stress,
and cellular energy status were investigated in human dia-
phragms after mechanical ventilation, in order to explore
the potential mechanisms of ventilator-induced diaphrag-
matic dysfunction [12]. We need more molecular evidence
to describe dysfunction of genes, proteins, cellular orga-
nelles, cells, or interactions between and refresh “old”
applications of clinical monitors or therapies.
I am pleased and honored to be co-editor of the journal
Translational Respiratory Medicine with Dr Michael
Matthay, a close friend, supportive colleague, and valuable
mentor for my post-doctoral education. Translational
Respiratory Medicine is an additional but unique opportun-
ity for scientists and clinicians who work on pulmonary dis-
eases to publish their outstanding findings, initiative results,
and critical and perceptive opinions in the journal. In initi-
ating the journal, we would like to express our special
appreciations to all colleagues for their encouragement,
support, comments, suggestions and contributions. With
the support of our Associate Editors and Editorial Board
Members, we have enough reason to believe that Transla-
tional Respiratory Medicine will be one of the leading plat-
forms to translate basic sciences associated with respiratory
diseases into clinical applications and benefit the healthcare
of humans.
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